Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease... (also undergoingevaluation in human clini...)

HOME >> MEDICINE >> TECHNOLOGY

Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor

Date:10/26/2008

also undergoing evaluation in human clinical trials.

"The emergence of our first clinical candidate is an important milestone for Sequoia and indicative of the tremendous progress we've made during the past 12 months," said Steve Skolsky, president and chief executive officer of Sequoia. "We're very pleased at the speed with which we have brought our drug candidates to human trials, following the successful filing of two investigational new drug applications in 2007, one for SPI-256, and a second for our proprietary pharmacokinetic enhancer, SPI-452."

About Sequoia Pharmaceuticals, Inc.

Sequoia Pharmaceuticals discovers and develops unique antiviral drugs that potently inhibit the most prevalent form of viruses and prevent the emergence of drug-resistant viruses. Sequoia's core expertise of structure- and target-based design facilitates the efficient discovery of multiple NCE's with a small team of discovery scientists. Its current drug pipeline focuses on HIV/AIDS and HCV-induced hepatitis. Sequoia is also developing a unique series of pharmacokinetic enhancers (PKEs) which have potential application in a wide range of therapy areas, including use in combination with currently marketed and experimental antiviral therapies.

Sequoia Pharmaceuticals has two investigational new drug applications (INDs) filed with the Food and Drug Administration. The first IND is for SPI-256, an HIV protease inhibitor in Phase 1 clinical development. The second IND is for SPI-452, a pharmacokinetic enhancer in Phase 1 clinical development.

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:

Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease...(also undergoingevaluation in human clini...),Health